Dubermatinib

DB15187InvestigationalSmall molecule

Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).

Formula / weight: C₂₄H₃₀ClN₇O₂S · 516.06 g/mol (avg)
Code names: TP-0903

Resolves to

Compound

UNII14D65TV20JCAS1341200-45-0ChEMBLCHEMBL2022968

Structure

InChIKeyYUAALFPUEOYPNX-UHFFFAOYSA-NSMILESCN(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(NC2=CC=C(CN3CCN(C)CC3)C=C2)=NC=C1Cl

Targets

P30530AXL

What you can answer from here — as of October 30, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dubermatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account